Phase 3 Recruiting NIH
This phase III trial compares the effect of adding chemotherapy to immunotherapy (pembrolizumab) versus immunotherapy alone in treating patients with stage IIIB-IV lung cancer. Immunotherapy with monoclonal antibodies, such as pembrolizuma…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06096844
Sites in Kentucky: - University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
- UofL Health Medical Center Northeast — Louisville, Kentucky
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Kentucky: - Baptist Health Hardin — Elizabethtown, Kentucky
- University of Kentucky/Markey Cancer Center — Lexington, Kentucky
- The James Graham Brown Cancer Center at University of Louisville — Louisville, Kentucky
- Norton Brownsboro Hospital and Medical Campus — Louisville, Kentucky
- UofL Health Medical Center Northeast — Louisville, Kentucky
Phase 2, Phase 3 Recruiting Industry
The Phase 2 portion of this study evaluates the efficacy and safety of MRTX849 monotherapy and in combination with pembrolizumab in cohorts of patients with advanced NSCLC with KRAS G12C mutation and any PD-L1 TPS and who are candidates fo…
Sponsor: Mirati Therapeutics Inc.
NCT ID: NCT04613596
Sites in Kentucky: - Lexington Medical Cancer Center Hematology/Oncology — Lexington, Kentucky
- University of Louisville — Louisville, Kentucky
- Local Institution - 007-388-A — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of ARTEMIDE-Lung02 is to assess the efficacy and safety of rilvegostomig in combination with platinum-based chemotherapy for the first-line (1L) treatment of patients with locally advanced or metastatic squamous non-small cell …
Sponsor: AstraZeneca
NCT ID: NCT06692738
Sites in Kentucky: - Research Site — Lexington, Kentucky
- Research Site — Lexington, Kentucky
- Research Site — Louisville, Kentucky
- Research Site — Louisville, Kentucky
Phase 3 Recruiting Industry
The goal of this study is to evaluate intismeran autogene plus pembrolizumab versus placebo plus pembrolizumab for the adjuvant treatment of margin negative, completely resected Stage II, IIIA, IIIB (with nodal involvement \[N2\]) non-smal…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06077760
Sites in Kentucky: - Saint Elizabeth Healthcare ( Site 0092) — Edgewood, Kentucky
- The University of Louisville, James Graham Brown Cancer Center ( Site 0037) — Louisville, Kentucky
Phase 3 Recruiting Industry
The purpose of this study is to compare the efficacy of Nivolumab and Relatlimab in combination with chemotherapy to Pembrolizumab with Chemotherapy in participants with stage IV or recurrent Non-squamous Non-small Cell Lung Cancer with PD…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT06561386
Sites in Kentucky: - Saint Elizabeth Medical Center Edgewood — Edgewood, Kentucky
- Baptist Health Lexington — Lexington, Kentucky
- Local Institution - 0502 — Paducah, Kentucky
Phase 2, Phase 3 Recruiting Industry
The purpose of this study is to compare the clinical benefit of the combination of Navlimetostat (BMS-986504) (a selective MTA-cooperative inhibitor of PRMT5) plus pembrolizumab and chemotherapy versus placebo plus pembrolizumab and chemot…
Sponsor: Bristol-Myers Squibb
NCT ID: NCT07063745
Sites in Kentucky: - Baptist Health Lexington — Lexington, Kentucky
- University of Kentucky Chandler Medical Center — Lexington, Kentucky
Phase 3 Recruiting Academic/Other
To Determine if SAbR improves survival over SR in High Risk Operable Stage I NSCLC
Sponsor: University of Texas Southwestern Medical Center
NCT ID: NCT02468024
Sites in Kentucky: - University of Kentucky Health Care — Lexington, Kentucky
- University of Louisville Physicians — Louisville, Kentucky
Phase 2, Phase 3 Recruiting Industry
This is a Phase 2/3, multisite, randomized, open-label study in participants with first-line non-small cell lung cancer (NSCLC). This study includes two substudies (substudy A and substudy B) that will recruit participants according to his…
Sponsor: BioNTech SE
NCT ID: NCT06712316
Sites in Kentucky: - Baptist Health Hardin — Elizabethtown, Kentucky
Phase 3 Recruiting Industry
The goal of this clinical study is to learn more about the study drug sacituzumab govitecan (SG; Trodelvy®; GS-0132; IMMU 132), versus standard of care (SOC) in participants with previously treated extensive stage small cell lung cancer (E…
Sponsor: Gilead Sciences
NCT ID: NCT06801834
Sites in Kentucky: - Northwest Cancer Centers — Dyer, Kentucky
- St. Claire Regional Medical Ce — Morehead, Kentucky
- Owensboro Health Mitchell Memorial Cancer Center — Owensboro, Kentucky
Phase 2 Recruiting Network
This phase II trial tests how well biomarker tests on patients tumor tissue works in selecting personalized treatments for patients with extensive stage small cell lung cancer (ES-SCLC). Biomarker tests look for certain features in cancer …
Sponsor: SWOG Cancer Research Network
NCT ID: NCT06769126
Sites in Kentucky: - Baptist Health Corbin — Corbin, Kentucky
- Baptist Health Lexington — Lexington, Kentucky
- Baptist Health Hamburg — Lexington, Kentucky
Phase 1, Phase 2 Recruiting Industry
This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combinatio…
Sponsor: Inhibrx Biosciences, Inc
NCT ID: NCT04198766
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
Phase 2 Recruiting Industry
This is a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung cancer
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT04614103
Sites in Kentucky: - University of Louisville — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
This is a study to investigate the efficacy and safety of an infusion of IOV-4001 in adult participants with unresectable or metastatic melanoma or advanced non-small-cell lung cancer (NSCLC).
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT05361174
Sites in Kentucky: - University of Louisville — Louisville, Kentucky
Phase 2 Recruiting Industry
The main objective of the study will be to evaluate the efficacy of sutetinib maleate capsules in participants with locally advanced or metastatic non-small cell lung cancer NSCLC (uncommon EGFR mutations only).
Sponsor: Teligene US
NCT ID: NCT06010329
Sites in Kentucky: - Norton Cancer Institute - Downtown — Louisville, Kentucky
Phase 1, Phase 2 Recruiting Industry
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetic, pharmacodynamic, preliminary anti-tumor activity, and to determine the recommended Phase II dose (RP2D) of the ALE.P03 monotherapy in adult patients with s…
Sponsor: Alentis Therapeutics AG
NCT ID: NCT07169734
Sites in Kentucky: - Norton Cancer Institute - Norton Healthcare Pavilion — Louisville, Kentucky
Phase 2 Recruiting Industry
This is a Phase 2b, multicenter, open-label study to evaluate the safety and efficacy of Sutetinib Maleate Capsule in Locally Advanced or Metastatic NSCLC (Non-resistant Uncommon EGFR Mutations Only, Including L861Q, G719X, and/or S768I)
Sponsor: Teligene US
NCT ID: NCT05168566
Sites in Kentucky: - Baptist Health — Louisville, Kentucky
Phase 2 Recruiting Industry
Researchers are investigating new treatments for untreated advanced non-small cell lung cancer (NSCLC), which is the most common form of lung cancer and lung cancer that has spread beyond surgical removal. Standard treatments include immun…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06731907
Sites in Kentucky: - University of Kentucky ( Site 0019) — Lexington, Kentucky
Phase 1, Phase 2 Recruiting Industry
This is a phase Ib/II, multicenter, open-label study of YL201 combined with atezolizumab. The study will include 2 parts. Part 1 of the study is a dose escalation in participants with previously untreated ES-SCLC to determine the safety an…
Sponsor: MediLink Therapeutics (Suzhou) Co., Ltd.
NCT ID: NCT07407933
Sites in Kentucky: - Site 1004 — Louisville, Kentucky
Phase 2 Recruiting Industry
Researchers are looking for new ways to treat metastatic nonsquamous non-small cell lung cancer (NSCLC) that has been treated before. Metastatic means the cancer has spread to other parts of the body. Nonsquamous means the cancer did not s…
Sponsor: Merck Sharp & Dohme LLC
NCT ID: NCT06780085
Sites in Kentucky: - University of Kentucky Chandler Medical Center ( Site 0019) — Lexington, Kentucky
Phase 1, Phase 2 Recruiting Industry
This is a Phase I/II, open-label, non-randomized, multi-center study in patients with extensive-stage small cell lung cancer (ES-SCLC) to determine the recommended dose(s) (RD) and to evaluate the safety, tolerability and preliminary effic…
Sponsor: Novartis Pharmaceuticals
NCT ID: NCT07564401
Sites in Kentucky: - University of Kentucky — Lexington, Kentucky
Phase 1, Phase 2 Recruiting Industry
Indication:Patients with Advanced c-MET-positive Non-Small Cell Lung Cancer Phase Ib (China only): Approximately 90 patients Phase Ⅱ (globally): Approximately 78 evaluable patients; addition of at least 6 patients in Safety Run-in (US only)
Sponsor: Haihe Biopharma Co., Ltd.
NCT ID: NCT04270591
Sites in Kentucky: - Norton Cancer Institute — Louisville, Kentucky
- The Oncology Institute of Hope & Innovation — Louisville, Kentucky
Phase 1 Recruiting Industry
This is a multicenter Phase 1b, open label, dose-escalation and cohort-expansion study, evaluating the safety, tolerability, pharmacokinetics (PK), preliminary antitumor activity, and effect of biomarkers of zanzalintinib administered alon…
Sponsor: Exelixis
NCT ID: NCT05176483
Sites in Kentucky: - Exelixis Clinical Site #122 — Louisville, Kentucky
Phase 1 Recruiting Industry
The purpose of this study is to learn about the safety and effects of the study medicine (called Mevrometostat) for the possible treatment of Relapsed/ Refractory Small Cell Lung Cancer (SCLC), Castration Resistant Prostate Cancer (CRPC) a…
Sponsor: Pfizer
NCT ID: NCT03460977
Sites in Kentucky: - Norton Cancer Institute - Downtown — Louisville, Kentucky
- Norton Cancer Institute, Norton Healthcare Pavilion — Louisville, Kentucky
- Norton Hospital — Louisville, Kentucky
Phase 1 Recruiting Industry
Phase 1 dose escalation and expansion study of CLSP-1025, a first-in-class HLA-A\*02:01 specific T cell engager (TCE) targeting solid tumors that harbor the p53 R175H mutation.
Sponsor: Clasp Therapeutics, Inc.
NCT ID: NCT06778863
Sites in Kentucky: - University of Kentucky Markey Cancer Center — Lexington, Kentucky